CVE-2026-41360OpenClaw before 2026.4.2 contains an approval integrity vulnerability in pnpm dlx that fails to bind local script operands consistently with pnpm exec flows.
Updated under an hour ago ()
Does this affect you?
It affects openclaw. Add what you run to find out whether that includes you.
No exploitation reported and no EPSS estimate yet.
Do this next
Free account, 1 product
OpenClaw before 2026.4.2 contains an approval integrity vulnerability in pnpm dlx that fails to bind local script operands consistently with pnpm exec flows. Attackers can replace approved local scripts before execution without invalidating the approval plan, allowing execution of modified script contents.
- CVSS
- 6.7 MEDIUM (v3.1, NVD)CVSS:3.1/AV:L/AC:H/PR:L/UI:R/S:U/C:H/I:H/A:H
- Weakness (CWE)
- CWE-367
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- Not loaded for this CVE
- Assigned by
- Not given
- NVD analysis
- Analyzed
- Record last updated
- Jun 17, 2026
- First seen by InfoSec Signals
- Oct 9, 2026
Affected products
openclaw openclaw openclaw:openclaw | before 2026.4.2 | NVD |
References
- https://github.com/openclaw/openclaw/commit/176c059b05357df1bc09d4328a2380670859eeffpatch
- https://github.com/openclaw/openclaw/security/advisories/GHSA-w6wx-jq6j-6mcjvendor-advisory
- https://www.vulncheck.com/advisories/openclaw-approval-integrity-bypass-in-pnpm-dlx-local-script-bindingthird-party-advisory
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.